These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21387109)

  • 1. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
    Harrop R; Shingler WH; McDonald M; Treasure P; Amato RJ; Hawkins RE; Kaufman HL; de Belin J; Kelleher M; Goonewardena M; Naylor S
    Cancer Immunol Immunother; 2011 Jun; 60(6):829-37. PubMed ID: 21387109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
    Harrop R; Treasure P; de Belin J; Kelleher M; Bolton G; Naylor S; Shingler WH
    Cancer Immunol Immunother; 2012 Dec; 61(12):2283-94. PubMed ID: 22692758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
    Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
    Amato RJ; Hawkins RE; Kaufman HL; Thompson JA; Tomczak P; Szczylik C; McDonald M; Eastty S; Shingler WH; de Belin J; Goonewardena M; Naylor S; Harrop R
    Clin Cancer Res; 2010 Nov; 16(22):5539-47. PubMed ID: 20881001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
    Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
    J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
    Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
    Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
    J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
    JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.
    Hawkins RE; Macdermott C; Shablak A; Hamer C; Thistlethwaite F; Drury NL; Chikoti P; Shingler W; Naylor S; Harrop R
    J Immunother; 2009 May; 32(4):424-9. PubMed ID: 19342962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Rini BI; Stenzl A; Zdrojowy R; Kogan M; Shkolnik M; Oudard S; Weikert S; Bracarda S; Crabb SJ; Bedke J; Ludwig J; Maurer D; Mendrzyk R; Wagner C; Mahr A; Fritsche J; Weinschenk T; Walter S; Kirner A; Singh-Jasuja H; Reinhardt C; Eisen T
    Lancet Oncol; 2016 Nov; 17(11):1599-1611. PubMed ID: 27720136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
    Amato RJ; Stepankiw M
    Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
    Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
    J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development.
    Kim DW; Krishnamurthy V; Bines SD; Kaufman HL
    Hum Vaccin; 2010 Oct; 6(10):784-91. PubMed ID: 20975327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
    Mai HX; Mei GH; Zhao FL; Li BT; Tang YY; Zhang B; Xu XJ; Chen LJ
    J Cancer Res Ther; 2018 Jun; 14(Supplement):S427-S432. PubMed ID: 29970701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.
    Tykodi SS; Thompson JA
    Expert Opin Biol Ther; 2008 Dec; 8(12):1947-53. PubMed ID: 18990081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
    Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
    J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.